During its fourth-quarter earnings call this week, Inspire Medical disclosed that it has become the subject of a civil probe ...

After calling Rockville, Maryland, home for more than eight years, Big Pharma GSK is planning to move its vaccine and ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

After offering a deep dive last year into the recipe behind its lead lung fibrosis candidate, Insilico Medicine is now giving ...

Tasso, maker of at-home blood sample collection systems, is launching the next generation of its devices that aim to support ...

The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...

Incyte has broken off its immuno-oncology deal with Agenus. The step, which follows a series of program terminations, will ...

Inventiva is going all-in on its metabolic-associated steatohepatitis (MASH) drug lanifibranor —but half of its employees won ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

Despite the failure of an eczema trial in December, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky.

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...